With a rich pipeline of hundreds of candidate therapeutics in all phases of clinical development and evaluation, across all platform modalities AND potentially thousands of genetic diseases treatable by gene therapies, I share this article discussing how to manufacturing speed can be ramped up with platform processes. (Cell & gene therapy not my area of expertise at all.) Expert views are welcome!
Anne
Comentarios